Hematide/peginesatide is Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients.
Affymax and Takeda said that the payments were triggered by the achievement of database lock in the Pearl and Emerald Phase 3 clinical trials, which evaluated Hematide to treat anemia in chronic renal failure patients.
According to Affymax Hematide is the company’s first product candidate to enter the clinic and has been evaluated in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure.
Further, Affymax and Takeda Pharma are collaborating on the development of Hematide and is expected to co-commercialise the product in the US upon approval.
However, Takeda Pharma holds an exclusive license to develop and commercialise Hematide outside the US, including Japan.
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions.